HOME >> BIOLOGY >> NEWS
New antimalarial combination confirms its potential use in treating drug-resistant malaria

three-day treatment period; and a second study will compare CDA to Lapdap alone. If the development of CDA is successful, it is expected to be available in 2008 as a convenient, once-daily dose. CDA will be made available to the public sector of malaria-endemic countries at preferential prices in order to maximise its availability to those in need.

CDA is being developed in collaboration with GlaxoSmithKline (GSK), the World Health Organization's Special Programme for Research and Training in Tropical Diseases (WHO/TDR), Medicines for Malaria Venture (MMV), the University of Liverpool, Liverpool School of Tropical Medicine and the London School of Hygiene & Tropical Medicine.

Dr. Robert Ridley, Director of WHO/TDR, stated, "The collaboration between WHO/TDR, MMV, GSK and our academic partners has enabled us to combine resources and expertise to speed the development of CDA."

"GSK is committed to research and development into treatments for diseases of the developing world," said Dr. Lynn Marks, Senior Vice President, Infectious Diseases Medicine Development Centre for GSK. "Public-private partnerships, such as this one for CDA, are vital in ensuring that urgently needed medicines are made available as quickly and safely as possible."


'"/>


15-Nov-2005


Page: 1 2

Related biology news :

1. Cost-effectiveness study of three antimalarial drug combinations in Tanzania
2. Research milestone brings goal closer of cheap antimalarial drug for developing world
3. $43 million from Gates Foundation to produce inexpensive antimalarial drug for Third World
4. Cetuximab and irinotecan combination increases survival in metastatic colorectal cancer
5. New study suggests promising drug combinations for sleeping sickness
6. Recombination protein dynamics observed with single monomer resolution
7. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
8. New combination treatment induces regression of prostate cancer
9. Avelox as effective as Levofloxacin combination therapy for severe community-acquired pneumonia
10. New observational study suggests use of combination vaccines may improve immunization coverage rates in infants
11. Pesticide combinations imperil frogs, probably contribute to amphibian decline

Post Your Comments:
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
(Date:6/24/2015)... YORK , June 24, 2015 The ... rate. The major drivers for the market include growth ... number of new drug launches. Over the years, the ... increased. Between 2001 and 2010, the FDA approved 225 ... according to WIPO, Europe accounted ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
(Date:7/1/2015)... 2015   Decision Resources Group finds ... Otezla are its oral administration, alternative mechanism of ... surveyed rheumatologists. Otezla was the first oral therapy ... active psoriatic arthritis in the United ... includes conventional oral treatments including disease-modifying antirheumatic drugs ...
(Date:7/1/2015)... and BANGALORE, India , July 1, ... company that uses next generation sequencing technology to empower ... A. Storrer as chief executive officer. In his ... be responsible for all strategy, business expansion and worldwide ... has served as Strand,s chairman and CEO since its ...
(Date:7/1/2015)... 1, 2015  Axovant Sciences Ltd. (NYSE:  AXON), ... treatment of dementia, today announced that the company ... at 5:45 p.m. EDT following its presentation of ... Conference 2015 (AAIC). The event ... Dr. Lawrence Friedhoff , Chief Development Officer, ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan contest will ask ... to innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will ... and a period of expert mentorship from a senior industry figure drawn from the ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: